Home
PVLA

PVLA

Palvella Therapeutics Inc. Common Stock

as of 12-05-2025 3:43pm EST

$100.16

+$6.36

+6.78%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Chart Type:

Time Range:

Founded:	2015	Country:	United States
Employees:	N/A	City:	WAYNE
Market Cap:	1.1B	IPO Year:	N/A
Target Price:	$124.25	AVG Volume (30 days):	258.4K
Analyst Decision:	Strong Buy	Number of Analysts:	16
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-3.53	EPS Growth:	N/A
52 Week Low/High:	$11.17 - $106.71	Next Earning Date:	11-11-2025
Revenue:	N/A	Revenue Growth:	N/A
Revenue Growth (this year):	N/A	Revenue Growth (next year):	N/A

AI-Powered PVLA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold

Model Accuracy: 66.67%

66.67%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full PVLA Forecast & Prediction with Hourly Data

Compare PVLA vs Leading Stocks

See how PVLA stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free PVLA Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "PVLA Palvella Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.